Sentien Biotechnologies, Inc. Receives NIH Phase IIB SBIR Award

In News

Sentien Biotechnologies, Inc. has been awarded a Phase IIB award from the NIDDK for $2.98M to advance its lead product into a Phase I Clinical Trial.